Claritev CTEV 深 沪
等待开盘 08-21 09:30:00 美东时间
34.08
-1.310
-3.70%
华盛通- 最 高35.00
- 今 开35.00
- 成交量 9.44万股
- 最 低 33.9205
- 昨 收 35.39
- 总市值 5.78亿
- 52周最高 74.0699
- 市盈率 静 --
- 换手率 0.56%
- 52周最低 11.50
- 委 比 33.33%
- 总股本 1694.75万
- 历史最高 74.0699
- 量 比 0.63
- 振 幅 3.05%
- 历史最低 0.173
- 每 手 1
- 风险率 16.76%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Claritev Expands Collaboration With Marpai To Launch Pre, Post- Payment Integrity Services To Health Plans
Claritev Corporation (NYSE: CTEV), a healthcare technology, data, and insights company, today announced that Marpai, Inc. (OTCQX:MRAI) has expanded its relationship with Claritev to bring comprehensive pre- and post-payment integrity capabilities to the health plans and claims it administers.
08-17 21:05
Saudi Arabia's PIF adds Elon Musk's SpaceX in Q2
Saudi Arabia's sovereign wealth fund, PIF, initiated a new position in Elon Musk's Space Exploration Technologies (SPCX) during the second quarter. One of the largest and most impactful state funds, P...
08-15 00:04
美股大行评级 | 业绩大超预期！ CoreWeave、超微电脑、Lumentum绩后获多家大行上调目标价
今日重点评级关注：Canaccord Genuity：维持Sagimet Biosciences"买入"评级，目标价从49美元升至56美元；韦德布什：维持Zura Bio"跑赢大市"评级，目标价从15美元升至22美元
08-13 11:44
美股大行评级 | Take-Two、Csquare、Standard获多家大行首予买入评级！潜在涨幅215.32%！HC Wainwright.升Innate Pharma(IPHA)目标价至7美元
今日重点评级关注：HC Wainwright & Co.：维持Innate Pharma"买入"评级，目标价从5美元升至7美元；HC Wainwright & Co.：维持Immix Biopharma"买入"评级，目标价从20美元升至25美元
08-11 11:45
Claritev Analysts Raise Their Forecasts Following Q2 Earnings
Claritev Corp (NYSE:CTEV) on Friday reported better-than-expected second-quarter financial results and raised its FY26 sales guidance above estimates. Claritev reported quarterly losses of $3.49 per share which beat the analyst consensus estimate of losses of $4.21 per share. The company reported qu...
08-10 22:45
Citigroup Maintains Buy on Claritev, Raises Price Target to $45
Citigroup analyst Daniel Grosslight maintains Claritev (NYSE:CTEV) with a Buy and raises the price target from $40 to $45.
08-10 22:35
Claritev shares are trading higher after the company reported better-than-expected Q2 financial results and raised its FY26 sales guidance above estimates.
Claritev shares are trading higher after the company reported better-than-expected Q2 financial results and raised its FY26 sales guidance above estimates.
08-07 20:34
Claritev Raises FY2026 Sales Guidance from $985.000M-$1.000B to $1.000B-$1.020B vs $993.511M Est
Claritev (NYSE:CTEV) raises FY2026 sales outlook from $985.000 million-$1.000 billion to $1.000 billion-$1.020 billion vs $993.511 million estimate.
08-07 17:57
Claritev Q2 EPS $(3.49) Beats $(4.21) Estimate, Sales $257.478M Beat $244.813M Estimate
Claritev (NYSE:CTEV) reported quarterly losses of $(3.49) per share which beat the analyst consensus estimate of $(4.21) by 17.1 percent. This is a 8.4 percent increase over losses of $(3.81) per share from the same period last year. The company reported quarterly sales of $257.478 million which bea...
08-07 17:23
Claritev 2026财年第二季度业绩：营收增长之际调整后EBITDA利润率收窄
Claritev (NYSE: CTEV) 公布 2026 财年第二季度营收为 2.575 亿美元，同比增长 6.6%；同时，GAAP 每股亏损从去年同期的 3.81 美元收窄至 3.49 美元。经调整 EBITDA 增长 1.1% 至 1.558 亿美元，但由于服务及管理成本增速快于营收增速，利润率从 63.8% 降至 60.5%。经营性现金流改善至 9270 万美元，此外，公司还上调了 2026 财年营收、经调整 EBITDA 及自由现金流指引。
08-07 09:16
